Scott Gettinger
Yale Cancer Center(US)Yale University(US)Smilow Cancer Hospital(US)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Lung Cancer Research Studies, Cancer Genomics and Diagnostics, Colorectal Cancer Treatments and Studies
Most-Cited Works
- → Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer(2012)12,527 cited
- → Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer(2015)9,390 cited
- → Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients(2014)5,215 cited
- → Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors(2011)3,533 cited
- → Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology(2022)1,384 cited
- → Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer(2015)1,189 cited